Optimizing DDI Knowledge throughout Drug Development
Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…
CertaraJanuary 6, 2025
From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations
SVP, Client and Regulatory Strategy, Certara Dr. Karen Rowland Yeo is Senior Vice-President, Client &…
CertaraJanuary 3, 2025
Sneak Preview: Introducing TFL Studio
Get your preview of the upcoming Tables, Figures, and Listings (TFL) Module in Phoenix Cloud.…
CertaraDecember 5, 2024
GlobalSubmit eCTD 4.0 Webinars
The world of electronic regulatory submissions is about to change with the introduction of eCTD…
CertaraDecember 3, 2024
The Future of DIDB
Explore the future of the Drug Interaction Database (DIDB) in this on-demand webinar, featuring insights…
CertaraNovember 8, 2024
Improved Translation of Clinical TCE Dosing with Mechanistic Modeling
Abstract: Regulatory agencies recommend quantitative justifications for clinical dose selection. T-cell engagers (TCE) pose particular…
CertaraOctober 31, 2024
Applications of a QSP Model of LNP mRNA Delivery for the Treatment of Crigler-Najjar Syndrome Type 1
Applications of a QSP Model of LNP mRNA Delivery for the Treatment of Crigler-Najjar Syndrome Type 1
Abstract: Crigler-Najjar syndrome type 1 (CN1) is an autosomal recessive disease caused by a marked…
CertaraOctober 31, 2024
Guiding Target and Lead Optimization for a Molecular Glue Degrader
Learn how to optimize drug properties for protein degrader therapeutics by exploring system characteristics.
CertaraOctober 31, 2024
Capturing CAR T-cell Therapy Dynamics Through Mechanistic Modeling
Abstract: Chimeric antigen receptor T (CAR T)-cell therapy has shown remarkable success in treating various…
CertaraOctober 31, 2024
